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SUMMARY
There isaneedforphysical standards (referencematerials) toensurebothreproducibilityandconsistency in theproductionofsomaticcell types
fromhumanpluripotent stemcell (hPSC) sources.Wehaveoutlined theneed for referencematerials (RMs) in relation to theuniqueproperties
andconcernssurroundinghPSC-derivedproductsandsuggest in-houseapproachestoRMgenerationrelevant tobasic research,drugscreening,
and therapeutic applications. hPSCs have an unparalleled potential as a source of somatic cells for drug screening, diseasemodeling, and ther-
apeutic application.Undefinedvariationandproduct variability after differentiation to the lineageor cell typeof interest impedeefficient trans-
lationandcanobscure theevaluationof clinical safety andefficacy.Moreover, in theabsenceofa consistentpopulation, datagenerated from in
vitro studies couldbeunreliable and irreproducible. Efforts to devise approaches and tools that facilitate improved consistency of hPSC-derived
products, both as development tools and therapeutic products,will aid translation. Standards exist in bothwritten andphysical form; however,
becausemany unknown factors persist in the field, prematurewritten standards could inhibit rather than promote innovation and translation.
We focusedon thederivationof physical standardRMs.Weoutline theneed for RMsandassess the approaches to in-houseRMgeneration for
hPSC-derivedproducts,acritical tool for theanalysisandcontrolofproductvariationthatcanbeappliedbyresearchersanddevelopers.Wethen
explore potential routes for the generation of RMs, including both cellular and noncellular materials and novel methods that might provide
valuable tools tomeasure and account for variation.Multiparametric techniques to identify “signatures” for therapeutically relevant cell types,
such as neurons and cardiomyocytes that can be derived fromhPSCs, would be of significant utility, although physical RMswill be required for
clinical purposes. STEM CELLS TRANSLATIONALMEDICINE 2015;4:217–223
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PERSPECTIVES
INTRODUCTION
Human pluripotent stem cell (hPSC) technologies have a unique
potential to address the increasing burden of unmet clinical need
formany intractable diseases. However, a grasp of the fundamen-
tal biology, which is necessary to ensure invariant and reproduc-
ible, safe and effective cellular products from batch-to-batch and
patient-to-patient, has eluded our reach. The field generally lacks
standards that will enable scalable, automated manufacturing to
build regulatory confidence and meet clinical needs.
Written standards exist in a vast range of industries, enabling
dialogue between stakeholders via a common set of “rules” or
“guidelines.” Typically developed through consensus that emerges
through an incremental process of discussion and revision among
experts, standards can establish specifications, set minimum
requirements, and provide a route by which valid comparisons
can be made. Standards can also serve to protect the integrity of
manufacturers, stimulate consumer confidence, and facilitate the
uptake of new technologies into the market [1, 2]. Importantly,
physical standards or reference materials used for specific com-
parative purposes are needed to validate and provide a bench-
mark for assessments of product or analytical tools.
Outlining the need for routes to generating both developer-
specific and, where appropriate, consensus physical (material)
standards for stem cell translation has value for two primary rea-
sons. First, physical standardswill support andenable improved re-
producibility and product consistency in research. Currently, the
field, and biomedical research in general, suffers from issues of ir-
reproducibility [3, 4], which impede progress and effective collab-
oration and could damage the public perception of stem cell
research. Second, commercial and translational benefits will result
from incorporating standardization principles early in research and
development by building a base for quality assessment to prevent
undue delays throughout clinical trials because of deficiencies in
the necessary tools and data to meet regulatory requirements.
Therefore, approaches for the derivation of standards and, espe-
cially, physical (material) standards could benefit early-stage re-
searchers conducting preclinical phase investigation, as well as
those engaged further along the translation pathway. However,
it is vital to strike the proper balance to ensure that the benefits
of standardization are not achieved at the expense of hindering in-
novation. In the present report, we are not trying to identify the
preferred PSC line to generate clinical products nor a specification
for the optimal cell type. Instead,wehave focusedon theneedand
possiblemechanismsbywhichphysical standards, referencemate-
rials (RMs), can be produced to analyze and thereby facilitate the
consistent and reproducible generation of products from hPSCs.
Becauseconsensus (international) RMsmight have limited applica-
tionandwouldbemorechallenging toachieve,wehave focusedon
in-housedeveloper-specificRMsthatcanbegeneratedbyresearch
laboratories and companies alike that are engaged inpreclinical re-
search and that can be applied in clinical trials and beyond tomeet
regulatory expectations. These principles and approaches also
have application in drug screening and toxicology studies that
use PSC-derived somatic cells with underlying expectations for re-
producibility and consistency.
CLINICAL POTENTIAL OF PSC-DERIVED PRODUCTS
The utility of hPSCs in disease modeling is beginning to be dem-
onstrated, and some of thesemodels are now finding application
as drug screening tools (reviewed in [5–8]). However, it is the ap-
plicationofPSCs as a cell source for therapeutic intervention that
still garners the greatest enthusiasm within a healthcare con-
text. To date, embryonic stem cell (ESC)-derived products have
entered a limited number of clinical trials, pioneered by Geron
Corporation (Menlo Park, CA, http://www.geron.com; assets
now owned by Asterias Biotherapeutics) and more recently Ad-
vanced Cell Technology, Inc. (Santa Monica, CA, http://www.
advancedcell.com), with a Pfizer/University College London trial
that began in 2014 [8, 9]. Although Geron did not complete its
trial of ESC-derived oligodendrocyte precursors for acute spinal
cord injury owing to internal competing fund allocations, it pio-
neered a regulatory path and demonstrated the data require-
ment for testing PSC-derived products in humans [9]. This
exercise proved educational, not only for the private sector,
but also for the regulators themselves, who, until that time,
had had no experience evaluating the safety of hPSC-derived
products in actual patients.
Standards for hPSCs in their undifferentiated state are impor-
tant for cell banking, both to demonstrate comparability and to
show that cell lines are stable over time [10, 11]. A number of en-
gaging perspectives on standards for hPSCs have been reported
[10, 12–14]. However, because hPSCs in their undifferentiated
state will not be the final product delivered to research subjects
or patients, the standards should extend to validating early-stage
translational research and the manufacture and scale-up process
by which large numbers of somatic cells are derived from hPSCs.
Just as with any cell therapy, owing to the unique nature of each
product, written standards will have limited utility for hPSC-
derived products. Instead, material standards, generated on
a case-by-case basis, will be required to validate the process,
method, and product consistency. Although such material stand-
ards will be the responsibility of the developer andwill vary in ac-
cordance with the particular developer’s technology, product,
and target indication, a clearer understanding of the needs,
requirements, andpotential approachesbywhich thesematerials
standards could be produced will benefit academic researchers
and industry alike.
CHALLENGES OF HPSC TRANSLATION
The application of hPSC-derived products in a clinical setting has
been challenged by the numerous inherent and unique barriers
to translation, including scalability and manufacturability, and
a variety of regulatory challenges:
c Phenotypic and genetic instability
c Capacity to generate adult phenotypes
c Cost of cell culture processes
c Clarity of protection for intellectual property
c Differentiation efficiencies and time scales
c Tumorigenicity risks
c Immunological considerations
c Paucity regulatory and sponsor familiarity
c Limited positive cell therapy outcomes to date
c Each product must be considered by regulatory authorities on
a case-by-case basis
hPSCs are highly reactive to their external environment. They
can undergo significant changes in response to different culture
conditions, to extended time in culture, and after cryopreservation
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[15–17]. Stability is also a key issue, both genetic stability and the
physiological stability of hPSC-derived products. Compared with
cells harvested fromadultdonors, hPSC-derivedpopulationsmight
have an increased propensity for continued proliferation, differen-
tiation, and/ormaturation. This was exemplified by the increased
frequency of cyst formation from the ESC-derived oligodendro-
cyte precursor cell population inGeron’s preclinical animal stud-
ies, which resulted in the Food and Drug Administration (FDA)
placing the trial on hold. This issue was ultimately resolved by
an additional level of cell selection [18]. Furthermore, hPSCs
and their differentiated progeny have been demonstrated to
be highly heterogeneous at the population level, with differ-
entiation protocols asynchronously generating a variety of
cell types [19]. Researchers are focusing on the generation
of homogeneous-differentiated populations from hPSCs that
would be amenable to clinical demands. However, it has been ar-
gued that mixed populations might be preferable to a single cell
type in some cases, if the survival or efficacy of administered cells
will be enhanced by the presence of interacting cell types. It will
be more challenging to characterize and control the consistency
and quality ofmixed populations, acknowledging that the level of
heterogeneity in cell products will always exceed that of tradi-
tional smallmolecules. These inherent characteristics and current
methodologies all create significant challenges for the develop-
ment of RMs for hPSC-derived products.
The challenges to the translation of hPSC-derived products are
as follows:
STANDARDS AND REFERENCE MATERIALS
Standards fall into two main categories, written and physical
(material), which must be clearly distinguished (Fig. 1). Written
standards include codes of practice, standard operating proce-
dures, agreed terminology, guidelines, and pharmacopoeia
methods. Pharmacopoeia, particularly relevant to this discus-
sion, are a series of monographs and general chapters for active
substances that outline the minimum requirements, describing
the identity and permissible levels of impurities, in addition to
appropriate methods to define purity and potency, with accom-
panying expected ranges (USP, 2011). Pharmacopoeia can re-
quire the use of consensus physical (material) standards,
which currently only exist for smallmolecules anda limitednum-
ber of biologics. The single example of a cell therapymonograph
is currently being developed by the USP Convention for
sipuleucel-T (Provenge; Dendreon, Seattle, WA, http://www.
dendreon.com), a T-cell therapy for advanced prostate cancer
that has been authorized by the FDA, although approval of
the monograph could encounter challenges and application
might be limited (USP, 2013). A variety of local and regional
organizations are concerned with the publication of pharmaco-
poeia and/or the production of physical reference standards
(Table 1). In addition, organizations such as the World Health
Organization and the Joint Committee for Traceability in Labo-
ratory Medicine—the latter in the context of laboratory medi-
cine and in vitro diagnostics, can lead and coordinate in the
establishment of higher order international RM [20].
RMs are highly characterized physical materials used with
analytical methods for a specific comparison purpose and are a
global regulatory expectation [21–24]. Physical (material) standards
can be subsegmented into certified (consensus) and in-house
(developer-specific) materials (Fig. 1). Although certified RMs are
available for many biological substances, they have not yet been
produced for cell therapies. The National Institute for Biological
Standards and Control (NIBSC) has produced a RM of untouched
(enrichment using negative selection techniques to prevent activa-
tion)CD41cell-certifiedRM, intendedforuse in clinicaldiagnostics.
This standard comprises fixed peripheral blood mononucleated
cells prelabeled with a CD4 antibody conjugated to fluorescein
isothiocyanate (NIBSC, SS-222); this approach could have some
relevance for cell therapies, as discussed below [25]. Certified
(consensus) RMs might have application when applied to specific
characterization methodologies but are highly unlikely to have
a broad application, especially considering the need for case-by-
case development of cell therapies such as hPSC-derived products.
Therefore, we have focused exclusively on in-house (developer-
specific) RMs. There are two main categories of in-house,
developer-specific RMs, “product” and “method” (Fig. 1).
POTENTIAL APPROACHES TO DEVELOPING REFERENCEMATERIALS
FOR HPSC-DERIVED PRODUCTS
The aimof the present discussion is to support the development of
approaches and assays that will facilitate consistency and compa-
rability in the production of differentiated cell types, such as car-
diomyocytes, neurons, and T cells from hPSCs, or “hPSC-derived
products.”Batch-to-batch variation, if not assessedandcontrolled,
will affect the quality of clinical hPSC-derived products. Moreover,
Figure 1. Overview of standards. Standards are a set of guidelines,
rules, or requirements, typically set by a regulatory body or product
manufacturer. They ensure that either duringmanufacture of a prod-
uct or in the final product, some aspect, such as safety, performance,
or quality, is consistent. Standards are either written, in the form of
guidance, standard operating procedures, and pharmacopoeia, or
they are physical (material). Physical standards are characterized
materials used as a benchmark against which to compare attributes
of a product and ensure consistency. They can be agreed on across
organizations and countries (consensus) or can be developer-specific
and local (in-house) (i.e., the standards are only adopted within the
organization in question). These in-house material standards, called
RMs, are the focus of our review and can be further divided into
a product RM, which is a representative batch of the product, or
amethod (measurement) RM, which provides a reference for analyt-
ical measurements. Abbreviation: RM, reference material.
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approaches that enable the consistent production of differentiated
cells will also be of significant benefit to drug and toxicity screening.
The potential causes of variation in the production of somatic cells
from hPSCs are numerous. “Products,” such as cardiomyocytes, are
generated from hPSCs by a highly dynamic differentiation process
that might use a variety of methods [26], typically occurring via a
number of stages. Even when considering the production of one
specific product, fromone hPSC line, using a singlemethod, it is in-
evitable that the final product will demonstrate variability among
the individual batches. This variabilitywill arise in the formof variable
levels of heterogeneity and “purity” of cell types and in inconsisten-
cies in thedifferentiationand/ormaturationstageof theproduct.Ad-
ditionally, both genomic and phenotypic stability could demonstrate
variation.Wehavedetailed approaches to RMgeneration thatmight
mitigate the current inconsistency and irreproducibility concerns.
An overview of the possible approaches to establish RMs for
hPSC-derived products identified twomain categories: those that
use living, cellular RMs, either as product or method RMs, and
those involving nonliving, noncellular materials, such as beads
or DNA or RNA samples, as method RMs (Table 2).
Product Reference Material Approaches
“Product” RMs should be representative of the product and are
used to validate comparability assessments throughout the
product’s lifecycle, including process change and optimization,
and to detect process drift (Fig. 2A). Individual RMs will be
designed to assist in the assessment of the product identity or
its biological potency, and the respective purpose for the RMs
must be clear at the outset.
The typical approach,which is commonpractice in the pharma-
ceutical industry, is to generate primary and secondary RMs that
are samples of the product batch generated for preclinical and
then pivotal studies. Secondary RMs are the working samples
used as a comparator in the relevant tests.Once the samples have
been depleted, the secondary RM is generated from another
batch and, through rigorous characterization, determined to be
sufficiently comparable to the primary RM via a direct compari-
son. Ideally, the quantity of primary RM would be sufficient to
last for the lifecycle of the product (in some cases, more than
20 years). However, and as discussed below, limitations could
be present that would preclude this period of coverage.
A second potential method to product RM generation involves
a “pooling” approach, in which cells from a number of different
batches are pooled. If RMs are generated using a pooling ap-
proach, the differences due to heterogeneity within the product
will be averaged out, providing a broad-ranging background
against whichmeasurements can be assessed. This could be ben-
eficial in a number of circumstances.
In a limited number of cases, biologically equivalent cellular pop-
ulations might be suitable product RMs. For example, if CD41
T lymphocytesarederived fromhPSC lines,CD41T lymphocyteshar-
vested from healthy donors might be suitable as a product RM or,
potentially, as amethod RM for a limited number of assays. This ap-
proachmight only be appropriate for a limited number of cell types
that can be obtained from healthy donors without causing a detri-
mental effect. Although this approach might have potential utility,
it must be acknowledged that the heterogeneity in the “biologically
equivalent” RMs would need to be analyzed and accounted for.
The considerations of whether these approaches would be suit-
able, in addition to the critical criteria of relevance to the product,
include stability, feasibility, and cost. Stability will need to bemon-
itored over time and stability profiles determined so that new RM
can be prepared before expiry. Because the batch sizes for hPSC-
derived products are expected to be smaller than typically seen
with small molecules and even biologics, the amount of product
that can be stored as RM will also be limited. The practicalities
of RM quantity requirements will vary and should be mapped
out and planned for by developers. An additional challenge for
approaches that rely on cellular RM is that the cell banks of differ-
entiated products will need to be cryopreserved, which will affect
Table 1. Organizations concerned with the generation and/or oversight of reference materials, including a list of major organizations that play
a role in the production, guidance, and/or directives concerning reference materials for small molecule drugs and biologics
Organization Region Description Web address
National Institute for Biological Standards
and Control
United Kingdom The leading WHO International
Laboratory for Standards is responsible
for .90% of global WHO standards
http://www.nibsc.org
USP Convention US The official organization that sets
standards and generates reference
materials implemented by the FDA as law
in the United States, used globally in
.140 countries
http://www.usp.org/about-usp
World Health Organization International Publishes the International
Pharmacopoeia, which aims to harmonize
global pharmaceutical standards and
administers the establishment of
international reference materials
http://www.who.int/medicines/
publications/pharmacopoeia/
overview/en/
European Directorate for the Quality of
Medicines & Healthcare
Europe Responsible for the European
Pharmacopoeia commission, the
evaluation of manufacturer’s quality
dossiers for certification, and market
surveillance program
http://www.edqm.eu/en/
edqm-homepage-628.html
Pharmaceutical and Medical Device
Regulatory Science Society of Japan
Japan Produces and distributes Japanese
Pharmacopoeia Reference Standards as
prescribed in the Japanese Pharmacopoeia
(published by Pharmaceuticals and
Medical Devices Agency)
http://www.pmrj.jp/hyojun/html/
frm031.php?lang=e
Abbreviations: FDA, U.S. Food and Drug Administration; WHO, World Health Organization
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not only viability, but also, potentially, functional parameters. This
will becomean issue if theproduct is tobeused“fresh”but is lessof
a concern if the product will be cryopreserved as a part of the pro-
duction process.
Method Reference Material Approaches
“Method”RMsareused toqualify, validate, anddefine the accep-
tance criteria for specific assays, to calibrate methods and equip-
ment, and to identify method drift over time (Fig. 2B).
Cell lines could be valuable method RMs in some settings. An
example of such an approach is the use of embryonal carcinoma
line 2102Ep, which has a good stability profile in culture. This cell
line has demonstrated utility in flow cytometry assays for the
characterization of a rangeof hESCsby the International StemCell
Initiative [27], despite anumberof reportedbiological differences
between hESCs and the embryonal carcinoma line [14, 28]. This
approach might also be relevant for a number of differentiated
cell types, if an appropriate cell line is available or can be pro-
duced. Immortalization of primary cells to generate stable cell
lines will affect signaling pathways and some phenotypic charac-
teristics; therefore, the suitability of cell lines asmethod RMswill
depend on the application. It should also be acknowledged that
the standardization, characterization, and qualification of cell
lines as method RMs would require a considerable amount of
workup and validation.
Noncellular (nonviable) method RMs could include fixed cells,
beads, DNA/RNA samples, and reference cytokines. Fixed cells,
most suitably from a product sample, can be used as a RM for
assays that compare cell surface marker expression, such as the
clinical application of the NIBSC CD41 T cell sample for HIV testing,
and applications to assess heterogeneity/composition criteria
[25]. However, the process of fixation changes the properties of
the cell,which couldnegate its use as amethodRMcomparedwith
the nonfixed product in some flow cytometry-based assays. Bead-
based approaches have routinely been used for flow cytometry
purposes, to both calibrate and establish baseline readings for
cytometers and to apply compensation settings. However, bead-
based approaches also have stability issues and would most likely
need to be used in conjunction with a cellular method RM.
RM for molecular biology assays should be more readily achiev-
able, because DNA and RNA samples, in the appropriate conditions,
have demonstrated good stability profiles, are easily stored, and can
be generated in large quantities relative to the amount of material
required for any given assay. In most cases, method RMs for molec-
ular biology assayswould be produced from a sample of the product
batch. One issue to be considered is the selection of suitable positive
controls in assays such as reverse transcription polymerase chain re-
action (RT-PCR). Semiquantitativemeasurements of gene expression
are typically made in relation to the expression of “housekeeping
genes.” However, a number of studies have identified changes in
the expression levels of these presumably stable genes in concor-
dance with the differentiation status of hPSCs and other stem cell
types; therefore, these would be an unsuitable baseline for these
assays [29, 30]. Similarly, although microarray-based assays detect
the relative levelsof all transcripts in thegenome, theydonot identify
alternatively spliced transcripts thatmight be critical for cellular func-
tion.RNAsequencing (RNAseq) is increasing inpopularity andhas the
potential to identify splice variants and absolute amounts of tran-
scripts.AchallengeforanRNAseqapproach,however, is the largevar-
iation in theresults fromdifferentsequencing laboratories,aproblem
that must be solved by a normalization method before sequencing-
based assays can be reliable—another example of the need for phys-
ical reference materials to enable comparability testing. Written
standards that identify a consensusminimum requirement for quan-
titative RT-PCR and microarray assays have been described [31, 32].
Table 2. Potential approaches to generating reference materials for
PSC-derived products
RM category RM description Type Explanation
Product Primary/
secondary
Cellular Generated as per
product. Primary and
secondary RMs.
Secondary RM is used as
the working material
that, when depleted, is
replaced with product
from a new batch and
qualified against the
primary RM.
Product Pooled Cellular Generated as per
product. RMs are
produced from a pooled
bank of cells. A potential
benefit is that variability
is averaged across the
population.
Product/
method
Biological
equivalent
Cellular For a limited number of
cell types that can be
harvested from donors
noninvasively (e.g.,
from blood), biological
equivalent cell
populations can be used
as a RM (e.g., expression
of CD4 levels on
peripheral blood T cells
and on PSC-derived
T cells).
Method Cell lines Cellular Cells lines could have
application in a number
of characterization
assays.
Method Noncellular Noncellular Samples such as fixed
cells for cell surface
marker staining, DNA
samples for sequencing
or genotyping, and RNA
for expression profiling.
Not a physical
RM
“Virtual” Noncellular Use of transcriptome,
proteome,
phosphoproteome, or
epigenetic mapping to
generate a complex
data set that, when
computational
algorithms are applied,
identifies a product
“signature” (e.g.,
concept from PluriTest,
PSC scorecard) (data
from Mu¨ller et al. [33],
2011; Bock et al. [34],
2011).
In-house RM for hPSC-derived products will enable the analysis and
qualification of consistency andpromote reproducibility. Product RMsare
used to ensure that a product batch is representative of an intended
product and to identify process drift. Method RMs are used to validate
data derived from specific assays, define assay acceptance criteria, and as
a tool to detect method drift.
Abbreviations: PSC, pluripotent stem cell; RM, reference material.
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Reference cytokines, such as those used to calibrate enzyme-
linked immunosorbent assays (ELISAs), are available in some
instances in the form of certified (international) RMs. However,
although a reference cytokine can serve todefine standard curves
and therefore a link to a known concentration of that cytokine for
an assay such as an ELISA, the reference cytokine is not a RM for
the biological assay that results in cytokine release.
Although not a material standard, approaches that create
product “signatures” from complex data sets and applied algo-
rithms might have application in demonstrating comparability.
Examples of such an approach that has been developed to assess
(undifferentiated) iPSC populations by gene expression analysis
include the hPSC Scorecard and PluriTest, either by genome-
widemicroarray (PluriTest [33]) or PCRanalysis of a setof selected
genes (Scorecard [34]), establishing a typical geneexpressionpro-
file. Users analyze their samples via the same method (array or
PCR) and compare their samples to the established standard
generated, in this case, from previous product batches. Such
a comparison informs users regarding how similar their sample
profile is to the expected profile. This approachmight be suitable
for the assessment of hPSC-derived products, in which a devel-
operwouldperformagenearray (or other) analysis usingmultiple
samples from different product batches. Then, using a similar ap-
proach to that of the PluriTest, an expression signature for the
product would be generated with the identification of “acceptable”
levels of variation. This data set could then be used as a “virtual”
method RM when assessing the comparability of future product
batches using the samemethod, in the context of a specific product.
This approachwould facilitate amove away from the inaccurate use
of a limited set of cell surface markers, which are typically used to
characterize and identify cell populations. Clearly, this approach
would require validation and the application of a suitable RM.
ThemethodRMswehavedescribedwill typically display greater
stability profiles than product RMs owing to the inherent plasticity
of living cells and their responsiveness to the environment. Feasi-
bility factors, including the ability togenerate sufficient batch sizes,
will also be more amenable to method RM approaches, which
should, in general, also carry lower costs. A rational mix ofmethod
RMs fordifferent assayswithin theoverall characterizationprocess
and robust product RMs will be required.
A final consideration is how the datawill bemade available and
managed once themethod and/or product RMshave been estab-
lished. Given that discussion has focused on development of in-
house RMs, external publication and management of data might
notbe required.However, rapiddisseminationofopenaccess and
peer-reviewed publications for community wide access would be
beneficial as a “formal” record and to catalyze multistakeholder
dialogue. Eventually, it might be possible to develop online data
repositories managed by experts in both research and regulation
that would act as a centralized resource.
The approaches we have outlined are by nomeans exhaustive.
Innovative thinking is required to envisage novel routes to RMs
that would be appropriate to the unique characteristics of
hPSC-derived products and cell-based therapies. It is clear that
the different approaches will have varying levels of application,
depending on the specific product and clinical application.
CONCLUSION
Uncontrolled variability and irreproducibility are key consider-
ations for the translationof PSC-derived therapeutics and for the cell
therapy fieldmore broadly.We have outlined the need for RMs, dis-
cussed thepotential challenges facedbyhPSC-derivedproducts, and
identifiedpossibleapproachestoalleviateconsistencyandreproduc-
ibility concerns in the production of hPSC-derived products. A range
of cellular and noncellular approaches to product and method RM
generation can be envisioned and have been described here, includ-
ing relevantconsiderations. Theambitionbehindour report is for the
research community and tool providers to engage around these
requirementsandexisting industryandregulatorymodelsandtermi-
nology, such that potential approacheswill be assessed and incorpo-
rated intopractice,asappropriate,andthatnovel thinkingwill leadto
approaches that more satisfactorily fulfill the needs outlined.
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